Chemoprevention is the administration of agents to prevent induction and inhibit or delay progression of cancers. For prostate, as for other cancer targets, successful chemopreventive strategies require well-characterized agents, suitable cohorts, and reliable intermediate biomarkers of cancer for evaluating chemopreventive efficacy. Agent requirements are experimental or epidemiological data showing chemopreventive efficacy, safety on chronic administration, and a mechanistic rationale for the observed chemopreventive activity. On this basis, promising chemopreventive drugs in prostate include retinoids, antiandrogens, antiestrogens, steroid aromatase inhibitors, 5α-reductase inhibitors, vitamins D and E, selenium, lycopene, and 2-difluoromethylornithine. Phase II trials are critical for evaluating chemopreventive efficacy. Cohorts in these trials should be suitable for measuring the chemopreventive activity of the agent and the intermediate biomarkers chosen as endpoints. Many cohorts proposed for phase II trials are patients with previous cancers or premalignant lesions. For such patients, trials should be conducted within the context of standard treatment. Two cohorts currently used in phase II prostate cancer chemoprevention trials are patients with PIN and patients scheduled for prostate cancer surgery. Biomarkers should fit expected biological mechanisms, be assayed reliably and quantitatively, measured easily, and correlate to decreased cancer incidence. Protocols for adequately sampling tissue are essential. Changes in PIN provide prostate biomarkers with the ability to be quantified and a high correlation to cancer. PIN measurements include nuclear polymorphism, nucleolar size and number of nucleoli/nuclei, and DNA ploidy. Other potentially useful biomarkers are associated with cellular proliferation kinetics (e.g. PCNA and apoptosis), differentiation (e.g. blood group antigens, vimentin), genetic damage (e.g. LOH on chromosome 8), signal transduction (e.g. TGFα, TGFβ, IGF-I, c-erb B-2 expression), angiogenesis, and biochemical changes (e.g. PSA levels).

Keywords:
Prostate, Chemoprevention, Drug development
1.
Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 1998;48:6–29.
2.
Kelloff GJ, Boone CW, Malone WF, Steele VE, Doody LA: Introductory remarks: Development of chemopreventive agents for prostate cancer. J Cell Biochem 1992;16(suppl H):1–8.
3.
Bostwick D: Prostatic intraepithelial neoplasia: Current concepts. J Cell Biochem 1992;16(suppl H):10–19.
4.
Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN, Henderson BE: Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. Cancer Res 1998;58:4497–4504.
5.
O’Shaughnessy JA, Wittes RE, Burke G: Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 1991;9:2225–2232.
6.
Kelloff GJ, Johnson JJ, Crowell JA, Boone CW, DeGeorge JJ, Steele VE, Mehta MU, Temeck JW, Schmidt WJ, Burke G, Greenwald P, Temple RJ: Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 1995;4:1–10.
7.
Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, Dimery IW, Brown BW, Goepfert H: Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990;323:795–801.
8.
Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R, Doody LA: Surrogate endpoint biomarkers for phase II cancer chemoprevention trials. J Cell Biochem 1994;19:1–9.
9.
Lippman SM, Benner SE, Hong WK: Cancer chemoprevention. J Clin Oncol 1994;12:851–883.
10.
Kelloff GJ, Hawk ET, Crowell JA, Boone CW, Nayfield SG, Perloff M, Steele VE, Lubet RA, Sigman CC: Strategies for identification and clinical evaluation of promising chemopreventive agents. Oncology (Huntington) 1996;10:1471–1480, 1484.
11.
Kelloff GJ, Hawk ET, Karp JE, Crowell JA, Boone CW, Steele VE, Lubet RA, Sigman CC: Progress in clinical chemoprevention. Semin Oncol 1997;24:1–13.
12.
Kelloff GJ, Crowell JA, Hawk ET, Steele VE, Lubet RA, Boone CW, Covey JM, Doody LA, Omenn GS, Greenwald P, Hong WK, Parkinson DR, Bagheri D, Baxter GT, Blunden M, Doeltz MK, Eisenhauer KM, Johnson K, Longfellow DG, Knapp GG, Malone WF, Nayfield SG, Seifried HE, Swall LM, Sigman CC: Clinical development plan: Genistein. J Cell Biochem 1996;(suppl 26):114–126.
13.
Henderson BE, Ross RK, Shibata A, Paganin-Hill A, Yu MC: Environmental carcinogens and anticarcinogens; in Wattenberg L, Lipkin M, Boone CW, Kellof GJ (eds): Cancer Chemoprevention. Boca Raton, CRC Press, 1992, pp 1–317.
14.
Kelloff GJ, Boone CW, Steele VE, Fay JR, Sigman CC: Inhibition of chemical carcinogenesis; in Arcos J, Argus M, Woo Y (eds): Chemical Induction of Cancer: Modulation and Combination Effects. Boston, Birkhäuser, 1995, pp 73–122.
15.
Ruddon RW: The epidemiology of human cancers; in Ruddon RW (ed): Cancer Biology, ed 3. New York, Oxford University Press, 1995, chap 2, pp 19–60.
16.
Ghosh J, Myers CE: Arachidonic acid stimulates prostate cancer cell growth: Critical role of 5-lipoxygenase. Biochem Biophys Res Commun 1997;235:418–423.
17.
Liu XH, Yao S, Kirschenbaum A, Levine AC: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58:4245–4249.
18.
Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr, Brawley OW, Ford LG: Design of the prostate cancer prevention trial (PCPT). Control Clin Trials 1995;16:150–163.
19.
Pollard M, Luckert PH, Sporn MB: Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res 1991;51:3610–3611.
20.
Kadmon D: Chemoprevention in prostate cancer: The role of difluoromethylornithine (DFMO). Cell Biochem 1992;16(suppl H):122–127.
21.
Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. JAMA 1996;276:1957–1963.
22.
Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S, Rounder J: Decreased incidence of prostate cancer with selenium supplementation: Results of a double-blind cancer prevention trial. Br J Urol 1998;81:730–734.
23.
Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK: Prostate cancer and supplementation wit α-tocopherol and β-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440–446.
24.
Aquilina JW, Lipsky JJ, Bostwick DG: Androgen deprivation as a strategy for prostate cancer chemoprevention. J Natl Cancer Inst 1997;89:689–696.
25.
Giovannucci EG, Ascherio A, Rimm EB, Stampfer MJ, Colditz G, Wallett WC: Intake of carotinoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995;87:1767–1776.
26.
Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N: Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 1993;2:467–472.
27.
Meyskens FL Jr, Graham V, Chvapil M, Dorr RT, Alberts DS, Surwit E: A phase I trial of β-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia. J Natl Cancer Inst 1983;71:921–925.
28.
Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJA: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313–1316.
29.
McNeal JE, Bostwick DG: Intraductal dysplasia: A premalignant lesion of the prostate. Hum Pathol 1986;17:64–71.
30.
Bostwick DG, Brawer MK: Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 1987;59:788–794.
31.
Brawer MK: Prostatic intraepithelial neoplasia. Probl Urol 1990;4:392–407.
32.
Brawer MK, Bigler SA, Sohlberg OE, Nagle RB, Lange PH: Significance of prostatic intraepithelial neoplasia on prostate needle biopsy. Urology 1991;38:103–107.
33.
Brawer MK: Prostatic intraepithelial neoplasia. A premalignant lesion. Hum Pathol 1992;23:243–248.
34.
Lipkin M: Prototypic applications of intermediate endpoints in chemoprevention. J Cell Biochem 1992;16(suppl G):1–13.
35.
Westra WH, Sidransky D: Phenotypic and genotypic disparity in premalignant lesions: Of calm water and crocodiles. J Natl Cancer Inst 1998;90:1500–1501.
36.
Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, Clayman G, Lee JJ, Lee JS, Hittelman WN, Lippman SM, Hong WK: Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998;90:1545–1551.
37.
Boone CW, Bacus JW, Bacus JV, Steele VE, Kelloff GJ: Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate endpoints for clinical trials. Proc Soc Exp Med Biol 1997;216:151–166.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.